VivoSeq
Other

Opioids

0

Pipeline Programs

7

Active Trials

1

Companies Involved

Opioids is an early-stage landscape with 0 programs across 1 company. The most active players are Shionogi.

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

60/100

Attrition Rate

22/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

23

clinical trials

Completed9 · 39%
Terminated5 · 22%
Recruiting4 · 17%
Not yet recruiting2 · 9%
Enrolling by invitation1 · 4%
Unknown status1 · 4%
Other1 · 4%

Trial Activity

23 trials

Impacts of Opioids on Respiratory Drive During Sleep
Not yet recruiting··Phase 1·NCT06854211·26 enrolled
Opioids and Social Support Enhanced Extinction Effects
Enrolling by invitation·UUniversity of California, Los Angeles·Phase 1·NCT04166071·60 enrolled
PARASTOP - Paracetamol With Strong Opioids
Completed·OOslo University Hospital·Phase 3·NCT05051735·204 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)